TECENTRIQ™ (atezolizumab) is NOW FDA APPROVED for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma

TECENTRIQ™ (atezolizumab) is NOW FDA APPROVED for the treatment of patients with locally advanced or metastatic urothelial carcinoma who1:

• Have disease progression during or following platinum-containing chemotherapy
• Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

To learn more, please visit the following:

• www.TECENTRIQ.com
• https://www.genentech-access.com/hcp/brands/tecentriq.html
• or download the TECENTRIQ Approval Letter